BioCentury
ARTICLE | Clinical News

Keytruda unlikely to face pushback from clinicians in HCC

June 3, 2019 2:44 AM UTC

Despite a Phase III miss for Merck & Co.'s Keytruda pembrolizumab to treat hepatocellular carcinoma, enthusiasm for the PD-1 inhibitor in the indication remains, according to comments made Sunday at the American Society of Clinical Oncology meeting in Chicago.

In November, FDA granted accelerated approval to Keytruda from Merck & Co. Inc. (NYSE:MRK) to treat HCC in patients previously treated with Nexavar sorafenib based on the Phase II KEYNOTE-224 trial...